

Dénervation dopaminergique et polymorphisme de la COMT chez les patients parkinsoniens de novo. Plasma tau protein and biomarkers of amyloid precursor protein (APP) for the diagnosis and prognosis of Alzheimer's disease. Ancillary study under study BALTAZAR (Biomarker of AmyLoïd pepTide and AlZheimer's diseAse Risk).

<https://www.neurodegenerationresearch.eu/survey/denervation-dopaminergique-et-polymorphisme-de-la-comt-chez-les-patients-parkinsoniens-de-novo-plasma-tau-protein-and-biomarkers-of-amyloid-precursor-protein-app-for-the-diagnosis-and-prognosis-of/>

Principal Investigators

David GRABLI

Institution

APHP Paris

Contact information of lead PI

Country

France

Title of project or programme

Dénervation dopaminergique et polymorphisme de la COMT chez les patients parkinsoniens de novo. Plasma tau protein and biomarkers of amyloid precursor protein (APP) for the diagnosis and prognosis of Alzheimer's disease. Ancillary study under study BALTAZAR (Biomarker of AmyLoïd pepTide and AlZheimer's diseAse Risk).

Source of funding information

DGOS

Total sum awarded (Euro)

€ 197,000

Start date of award

xx/xx/2013

Total duration of award in years

3

Keywords

Research Abstract

Further information available at:

Types:

Investments < €500k

Member States:

France

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A